Table 1.
Demographic and baseline characteristics in children aged ≥ 6 to <12 years
| Characteristic | All patients | Symptomatic patients (baseline TSS ≥ 2) | ||
|---|---|---|---|---|
| MP‐AzeFlu (n = 264) | FP (n = 89) | MP‐AzeFlu (n = 124) | FP (n = 44) | |
| Age, n (%) | ||||
| ≥6 to <9 years | 128 (48.5) | 44 (49.4) | 63 (50.8) | 21 (47.7) |
| ≥9 to <12 years | 136 (51.5) | 45 (50.6) | 61 (49.2) | 23 (52.3) |
| Gender, n (%) | ||||
| Male | 158 (59.9) | 46 (41.7) | 81 (65.3) | 20 (45.5) |
| Race, n (%) | ||||
| Black/African American | 41 (15.5) | 16 (18.0) | 20 (16.1) | 7 (15.9) |
| White | 200 (75.8) | 67 (75.3) | 99 (79.8) | 35 (79.5) |
| Other | 23 (8.7) | 6 (6.7) | 5 (4.0) | 2 (4.5) |
| TSS, mean (SD) | 1.72 ± 0.76 | 1.77 ± 0.73 | 2.40 ± 0.35 | 2.36 ± 0.35 |
| Range | 0–3 | 0–3 | ||
TSS, total symptom score; SD, standard deviation.
MP‐AzeFlu: novel intranasal formulation of azelastine hydrochloride and fluticasone propionate (FP) in a single spray.